HER2 testing: a review of detection methodologies and their clinical performance (Q28280488)

0 references

Denise I Quigley

0 references

Raymond Tubbs

0 references

Daynna J Wolff

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

0 references

language of work or name

English

0 references

publication date

January 2007

0 references

published in

0 references

volume

0 references

issue

0 references

page(s)

53-64

0 references

cites work

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Biology of HER2 and its importance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Prognostic and predictive value of HER2/neu oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The long term prognostic significance of c-erbB-2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Molecular markers in Paget disease of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Role of HER2 gene overexpression in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

HER2/neu in the management of invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Current status of HER2 testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The clinical evaluation of HER-2 status: which test to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Targeted therapy in breast cancer: the HER-2/neu gene and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

The role of the epidermal growth factor receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53

Dysregulation of cellular signaling by HER2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.1.53